8-K: REGENXBIO Stockholders Elect Directors, Ratify Auditor, and Approve Executive Compensation & Equity Plan at Annual Meeting

REGENXBIO Inc. announced the results of its 2025 Annual Meeting of Stockholders, where all five proposals, including the election of directors, ratification of auditors, and approval of executive compensation and an equity incentive plan, were passed with strong shareholder support.

Summary

• REGENXBIO Inc. held its 2025 Annual Meeting of Stockholders on May 30, 2025, with approximately 82.4% of eligible shares (41,282,389 shares) represented.
• Four Class I directors – Allan Fox, Alexandra Glucksmann, Ph.D., Curran Simpson, and Jennifer Zachary – were elected to serve until the 2028 annual meeting.
• Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the year ending December 31, 2025, with 41,172,522 votes For.
• The compensation of the company's named executive officers was approved on an advisory basis, receiving 32,577,603 votes For.
• Stockholders voted, on an advisory basis, to hold future advisory votes on executive compensation every year, with 33,147,175 votes for the 'One Year' option.
• The REGENXBIO Inc. 2025 Equity Incentive Plan was approved by stockholders, with 27,395,802 votes For.

Sentiment

Score: 7

Explanation: The document reports routine annual meeting results where all management-backed proposals passed with strong shareholder support, indicating stable corporate governance and shareholder alignment. There are no negative surprises or new risks disclosed.

Positives

• High shareholder participation with 82.4% of shares represented at the Annual Meeting, indicating strong engagement.
• All four Class I director nominees were successfully elected with significant 'For' votes, demonstrating shareholder confidence in the board.
• The appointment of PricewaterhouseCoopers LLP as the independent auditor was overwhelmingly ratified, ensuring continuity and confidence in financial oversight.
• The advisory vote on executive compensation passed with strong support, suggesting alignment between executive pay practices and shareholder expectations.
• The approval of the 2025 Equity Incentive Plan provides the company with a key tool for attracting and retaining talent through equity-based compensation.

Future Outlook

Based on the advisory vote on executive compensation frequency, REGENXBIO Inc. will conduct future advisory votes on executive compensation on an annual basis until the next advisory vote regarding the frequency of such votes.

Management Comments

• "On the basis of the vote on this proposal and its alignment with the board of directors recommendation as disclosed in the Proxy Statement, the Company will conduct future advisory votes on the Companys executive compensation on an annual basis until the next advisory vote regarding the frequency of such advisory votes."

Industry Context

This filing is a routine corporate governance update common across all publicly traded companies, reflecting the standard process of holding annual stockholder meetings to elect directors, ratify auditors, and vote on executive compensation and equity plans. The high voter turnout and approval rates are generally positive indicators of stable corporate governance, consistent with well-managed companies in the biotechnology sector.

Comparison to Industry Standards

• The voter turnout of approximately 82.4% is robust and generally above average for U.S. public companies, indicating strong shareholder engagement compared to industry benchmarks.
• The overwhelming approval of director nominees and auditor ratification aligns with typical outcomes for established companies, suggesting no significant governance controversies or shareholder activism.
• The advisory approval of executive compensation and the decision to hold annual 'say-on-pay' votes are standard best practices in corporate governance, consistent with peer companies like Sarepta Therapeutics (SRPT) or Bluebird Bio (BLUE) which also prioritize regular shareholder input on compensation.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Confirms the election of directors, ratification of auditors, and approval of executive compensation and the equity incentive plan, providing clarity on corporate governance and potential future share dilution from the equity plan.
• **Management/Employees**: The approval of the 2025 Equity Incentive Plan directly impacts employees by providing a mechanism for equity-based compensation, which can incentivize performance and aid retention.

Next Steps

• The company will conduct future advisory votes on executive compensation on an annual basis.

Key Dates

Recommendation

Keywords

REGENXBIO, RGNX, Annual Meeting, Stockholders, SEC Filing, 8-K, Corporate Governance, Director Election, Auditor Ratification, Executive Compensation, Equity Incentive Plan, Proxy Statement, Biotechnology, Gene Therapy